Choroidal evaluation of FTLD-Tau and biomarker-determined Alzheimer's disease

脉络膜评估FTLD-Tau和生物标志物确定的阿尔茨海默病

阅读:2

Abstract

Frontotemporal lobar degeneration with tauopathy (FTLD-Tau) can present clinically similar to Alzheimer's disease but lacks a biomarker. Alzheimer's disease has been associated with choroidal thinning compared to controls. We compared the choroid of 25 probable FTLD-Tau (pFTLD-Tau) patients (42 eyes), 26 biomarker-determined probable Alzheimer's disease neuropathologic change (pADNC) patients (49 eyes), and 53 normal controls (80 eyes). Cerebrospinal fluid biomarkers determined presence of ADNC. All pFTLD-Tau patients had a syndrome highly associated with FTLD-Tau. Optical coherence tomography was performed with masked manual choroidal thickness (CT) measurements. With Image J, binarized images determined the choroidal vascularity index (CVI). Linear regression with generalized estimating equations to account for inter-eye correlation was performed. For pFTLD-Tau, pADNC, and controls, the subfoveal CT was 308.9, 286.0, and 301.5 μm, and CVI was 0.72, 0.72, and 0.73, respectively (all p > 0.05 for each group comparison). Adjusting for demographics, the CT and CVI were not significantly different between groups, including 13 CT measurement locations (all p > 0.05). Among pADNC patients, an exploratory analysis found a correlation between CVI and disease duration (Pearson r = 0.32, p = 0.04). We found no significant difference of CT or CVI between pFTLD-Tau, pADNC, and controls. Additional studies are warranted to evaluate how CVI relates to ADNC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。